老年早期乳腺癌患者激素治疗的启动与完成
本研究基于前瞻性机构数据库,纳入2010至2017年接受手术的590例≥65岁I期激素受体阳性乳腺癌患者,分析其启动与完成5年内分泌治疗的相关因素。结果显示76.8%患者启动内分泌治疗,其中69.5%完成至少5年;未启动与高龄、骨量减少和较低BMI相关,中断与高龄、未行腋窝手术、吸烟及婚姻状态相关。完成5年内分泌治疗者局部无复发生存率显著更优。
要点
- 高龄、骨量减少、较低BMI与未启动内分泌治疗相关。
- 高龄、未行腋窝手术、吸烟与内分泌治疗中断相关。
- 完成5年内分泌治疗者局部无复发生存率显著更优。
核心结论
- 高龄、骨量减少和较低BMI与未启动内分泌治疗相关,高龄、婚姻状态、腋窝手术和吸烟史预测内分泌治疗中断。
- 这些因素可能有助于指导关于省略辅助放疗的讨论。
研究设计与样本
- 使用前瞻性维护的机构数据库,识别2010至2017年接受手术的≥65岁I期激素受体阳性乳腺癌患者。
- 共纳入590例 eligible 患者,缺失数据采用多重插补,采用Kaplan-Meier分析和单因素及多因素logistic回归分析。
主要发现
- 453例(76.8%)启动内分泌治疗,其中315例(69.5%)完成至少5年治疗。
- 未启动内分泌治疗者年龄更大(平均77.02 vs 72.46岁;P < .001),BMI更低(平均25.36 vs 26.78 kg/m2;P = .008),双能X线吸收测定评分更低(平均-1.92 vs -1.58;P = .056),接受腋窝手术比例更低(64.2% vs 86.8%;P < .001)。
- 内分泌治疗中断与年龄更大(HR,1.082;95% CI,1.033-1.133;P = .001)、未行腋窝手术(HR,0.365;95% CI,0.146-0.915;P = .032)、吸烟(HR,1.636;95% CI,1.001-2.676;P = .05)相关。
- 单身或从未结婚者中断内分泌治疗的可能性更低(HR,0.281;95% CI,0.096-0.821;P = .020)。
- 完成5年内分泌治疗者局部无复发生存率(96.8%)显著优于提前停止者(87.7%;P = .01)和未启动者(88.7%;P < .001)。
临床怎么用
- 对于考虑省略辅助放疗的老年早期乳腺癌患者,应评估其启动和完成5年内分泌治疗的可能性。
- 高龄、骨量减少、较低BMI、吸烟、未行腋窝手术等因素可用于识别内分泌治疗依从性风险较高的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Clinical trials suggest that adjuvant radiation therapy (RT) may be omitted in women aged ≥65 years with early-stage, hormone-receptor-positive breast cancer, provided completion of 5 years of hormone therapy. However, at the time of RT consult, it is often unknown whether the patient will start hormone therapy or will start but not complete 5 years of therapy, either of which, if known in advance, would alter RT recommendations. We studied a cohort of patients who would have been eligible for RT omission to examine factors associated with declining or discontinuing hormone therapy. METHODS AND MATERIALS: Using a prospectively maintained institutional database, we identified patients aged ≥65 years who underwent surgery from 2010 to 2017 with stage I hormone-receptor-positive breast cancer. Patients were classified as having osteopenia or osteoporosis based on the lowest T-score on dual-energy x-ray absorptiometry. Missing data were replaced using multiple imputation. Recurrence and survival statistics were calculated using Kaplan-Meier analysis. Univariate and multivariate logistic regression analyses were used to assess factors associated with not starting or discontinuing hormone therapy. RESULTS: We identified 590 eligible patients. Of these, 453 (76.8%) started hormone therapy. Patients who did not start hormone therapy were older (mean age, 77.02 vs 72.46 years; P < .001), had a lower body mass index (mean, 25.36 vs 26.78 kg/m2; P = .008), had lower dual-energy x-ray absorptiometry scores (mean score, -1.92 vs -1.58; P = .056), and were less likely to undergo axillary surgery (64.2% vs 86.8%; P < .001). Of the 453 patients who started hormone therapy, 315 (69.5%) completed at least 5 years of therapy. Discontinuation of hormone therapy was associated with older age (hazard ratio [HR], 1.082; 95% CI, 1.033-1.133; P = .001), not undergoing axillary surgery (HR, 0.365; 95% CI, 0.146-0.915; P = .032), and smoking (HR, 1.636; 95% CI, 1.001-2.676; P = .05). Patients who were single or never married were less likely to discontinue hormone therapy (HR, 0.281; 95% CI, 0.096-0.821; P = .020). Patients who completed 5 years of hormone therapy had significantly better local recurrence-free survival (96.8%) than those who stopped early (87.7%; P = .01) or did not start hormone therapy (88.7%; P < .001). CONCLUSIONS: Older age, osteopenia, and lower body mass index were associated with not starting hormone therapy, while older age, marital status, axillary surgery, and smoking history predicted discontinuation of hormone therapy. These factors may guide discussions regarding the omission of adjuvant RT.
引用
- Karp JM, Schnabel F, Xiao J, et al. Initiation and Completion of Hormone Therapy in Older Women With Early-Stage Breast Cancer. Int J Radiat Oncol Biol Phys. 2026. PMID: 41690555. doi:10.1016/j.ijrobp.2026.01.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。